Harbour Investments Inc. Sells 87 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Harbour Investments Inc. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,457 shares of the medical research company’s stock after selling 87 shares during the quarter. Harbour Investments Inc.’s holdings in Thermo Fisher Scientific were worth $2,139,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Entropy Technologies LP boosted its stake in shares of Thermo Fisher Scientific by 111.1% in the 3rd quarter. Entropy Technologies LP now owns 16,519 shares of the medical research company’s stock valued at $10,218,000 after purchasing an additional 8,693 shares in the last quarter. Apollon Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 4.0% during the third quarter. Apollon Wealth Management LLC now owns 11,042 shares of the medical research company’s stock valued at $6,830,000 after buying an additional 423 shares during the last quarter. Bond & Devick Financial Network Inc. bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $202,000. Catalytic Wealth RIA LLC boosted its holdings in Thermo Fisher Scientific by 38.8% during the 3rd quarter. Catalytic Wealth RIA LLC now owns 5,890 shares of the medical research company’s stock valued at $3,643,000 after acquiring an additional 1,648 shares during the period. Finally, Chartwell Investment Partners LLC increased its stake in Thermo Fisher Scientific by 45.8% in the 3rd quarter. Chartwell Investment Partners LLC now owns 17,496 shares of the medical research company’s stock worth $10,823,000 after purchasing an additional 5,496 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Royal Bank of Canada cut their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Bernstein Bank boosted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Finally, Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Trading Up 0.2 %

Thermo Fisher Scientific stock opened at $541.90 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $455.22 and a 12 month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The business’s fifty day simple moving average is $591.27 and its two-hundred day simple moving average is $583.32. The company has a market capitalization of $207.28 billion, a price-to-earnings ratio of 33.97, a price-to-earnings-growth ratio of 3.57 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. During the same period in the prior year, the firm posted $5.69 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the transaction, the chief executive officer now owns 14,608 shares in the company, valued at $8,076,178.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.